Skip to main content
. 2014 Autumn;3(4):207–215.

Fig. 2.

Fig. 2.

Potential HCV vaccines in clinical phase development. The vaccines are based on either prophylactic or therapeutic usage in phase I, phase I/ II or phase II development (no HCV- specific vaccine has reached phase III development yet). The biological component(s) of the vaccine is listed on top of the arrow. Sponsor or company conducting the trial is listed at the end of arrow along with clinical ID number (http :// www. clinicaltrials.gov) (48). The article has been distributed under a Creative Commons license (Attribution 3.0 Unported (CC BY 3.0). The authors and the Nature Publishing Group are fully acknowledged